Medical devices and tools ("medtech") covers companies that make physical instruments used to diagnose, monitor, or treat patients — cardiac stents, orthopedic implants, surgical robots, imaging systems, glucose monitors — plus the "tools" adjacency: life-sciences instruments and lab consumables (sequencers, reagents, bioprocessing) that equip research and diagnostic labs. It is structurally distinct from pharma/biotech: the economic engine is engineering, manufacturing scale, regulatory clearance, and physician/customer behavior rather than a single patentable molecule. The core investing tension is that the best medtech businesses are slow, compounding, recurring-revenue franchises with deep moats — but they sit at the intersection of innovation cycles, hospital capital budgets, elective-procedure volumes, and reimbursement policy, any of which can stall an otherwise pristine story.

The structure of the sector

Medtech is not one industry but several with different economics:

• Large-cap diversified device makers — Medtronic, Johnson & Johnson MedTech, Abbott, Stryker, Boston Scientific. By device-segment revenue the recent leaders are roughly Medtronic (~$33B), J&J MedTech (~$32B), Abbott (~$28B), Stryker (~$23B), and Boston Scientific (~$17B), per FY2025 industry rankings (massdevice "10 largest medical device companies 2025"; figures vary by how each firm defines its device segment and which acquisitions are included). Siemens Healthineers, Becton Dickinson and GE HealthCare also rank in the global top 10. The global device market is estimated at roughly $604–719B in 2026 (Fortune Business Insights ~$605B; Precedence Research ~$720B — treat the spread as methodology-dependent, not precise).
• High-growth single-platform names — Intuitive Surgical (da Vinci robotics), DexCom/Insulet (diabetes), Inspire, Penumbra.
• Life-sciences tools & diagnostics — Thermo Fisher, Danaher, Agilent, Illumina, Bio-Rad. These sell to labs and pharma rather than to surgeons; their cycle tracks biopharma R&D spend, academic funding, and (recently) post-COVID destocking.

A useful lens is end-market exposure: essential/acute (pacemakers, stroke devices) tends to be defensive; elective (hip/knee replacements, aesthetics) and capital equipment (imaging, surgical-robot systems) are more cyclical.

How the business model works

The defining feature of premier medtech is the "razor-and-blade" installed-base model. A company places durable equipment — a surgical robot, an ablation generator, a sequencer — sometimes near break-even, then earns high-margin recurring revenue on the disposables, instruments, reagents, and service contracts that the installed base consumes for years. Service and consumable revenue commonly carry roughly 50–70% gross margins (MedDeviceGuide; treat as a cited range, not a hard number). This makes revenue more predictable and more defensible than one-off capital sales, and it is the single biggest reason the best names trade at premium multiples.

Three reinforcing moats sustain it: 1. Regulatory moat — devices cleared through the rigorous PMA pathway face high replication barriers. 2. Switching-cost / installed-base moat — once a hospital standardizes on a platform, the consumables and workflow lock it in. 3. Behavioral moat — surgeons trained on a specific device (Mako, da Vinci) are reluctant to switch.

Regulatory pathways (the value inflection)

US devices reach market via three FDA routes. The 510(k) clearance shows "substantial equivalence" to an existing predicate device — roughly 6–18 months and ~$50K–$400K, and the route for the large majority of devices (FDA; the often-quoted "~99% via 510(k)" figure is widely cited but should be read as "the dominant pathway"). De Novo handles novel low/moderate-risk devices with no predicate. PMA (premarket approval) is for high-risk Class III devices and demands clinical trials — commonly cited at ~3–7 years and $10–75M (TheFDAGroup, MedDeviceGuide). FDA risk classes map roughly to these: Class I (low risk, e.g. bandages), Class II (e.g. infusion pumps), Class III (life-sustaining implants). The EU's parallel system is the CE mark under MDR, with classes I, IIa, IIb, III. For investors, regulatory clearance is a valuation inflection — sources note company value can step up 2–5x on a major clearance as binary regulatory risk is removed (MedDeviceGuide; this is a deal-advisory rule of thumb, not a guarantee).

How it's used in practice

Analysts value medtech primarily on organic revenue growth and revenue quality, not on a pipeline lottery. The practical checklist:

• Organic growth rate — repeatedly cited as the single strongest predictor of the multiple.
• Recurring/consumable mix vs. lumpy capital equipment.
• Margin profile and operating leverage as the installed base scales.
• Moat type (PMA + behavioral + switching cost is the strongest combination).

On multiples, MedTech sits between pharma and healthcare services with unusually wide dispersion: large pharma often trades ~10–15x forward EBITDA, while devices run ~15–25x EV/EBITDA for high growth down to ~10–15x for mature names (IB-guide comps; ranges shift with rates and sentiment). Single-platform compounders like Intuitive Surgical have historically commanded far richer multiples on the durability of their consumable annuity. M&A is a constant: large caps routinely buy smaller innovators that have cleared the regulatory and reimbursement hurdles, making clearance/reimbursement milestones the key catalysts to track.

Adoption, debate & evidence

Medtech is one of the most consistently held long-term healthcare allocations precisely because the installed-base model produces durable compounding — this is broadly accepted, not contested. The genuine debates are:

• Defensive or cyclical? The "healthcare is recession-proof" claim is only partly true for devices. Essential/acute device demand is sticky, but elective procedures and hospital capital equipment fall when consumers defer care or hospitals freeze budgets — vividly demonstrated when elective volumes collapsed during COVID lockdowns. Life-sciences tools proved cyclical too, suffering post-pandemic destocking as customers worked down inventory.
• Reimbursement is the silent killer. A cleared device with no reimbursement code (CMS/Medicare coverage, coding, payment) often cannot sell. Sources stress this is especially lethal for startups — clearance ≠ adoption.
• Innovation displacement is real. The 2025–26 surge of pulsed-field ablation (PFA) for atrial fibrillation — both Boston Scientific (Farapulse) and Medtronic (Affera/PulseSelect) reporting steep growth, with Medtronic reporting ~80% YoY growth in Cardiac Ablation Solutions in Q3 FY2026 (~137% in the U.S.) per its February 2026 earnings release — shows how fast a new modality can reshuffle share and strand prior-generation products.

Strengths & limitations

Works best for: identifying durable compounders — companies with a large, growing installed base, high consumable mix, a PMA/behavioral moat, and steady mid-to-high single-digit organic growth. These tend to be lower-drama holdings than biotech.

Fails / traps:

• Treating all medtech as defensive — elective- and capex-exposed names sell off hard in downturns.
• Ignoring reimbursement and coding risk — the #1 misuse is celebrating an FDA clearance as if it were a revenue event.
• Paying a premium multiple into a technology-displacement cliff (the company whose flagship is the old modality).
• Overweighting tools/diagnostics without modeling the biopharma-funding and inventory cycle they depend on.

Sources

• massdevice, "10 largest medical device companies" (2025); iData Research, "Biggest MedTech Companies 2026" — revenue rankings.
• FDA, "Premarket Notification 510(k)"; TheFDAGroup, "PMA vs. 510(k)" — pathways, timelines, costs.
• MedDeviceGuide, "Medical Device M&A & Funding" and "Company Valuation: Methods, Multiples & Due Diligence" — razor-blade margins, valuation inflection, moats.
• ibinterviewquestions.com Healthcare IB Guide — MedTech vs. pharma multiple ranges.
• simplerqms, "FDA Medical Device Classification" and "EU MDR Classification" — risk classes / CE mark.
• Medtronic Q3 FY2026 earnings release (SEC 8-K, Feb 2026) and Boston Scientific electrophysiology results — PFA adoption.
• Defensive/cyclical and reimbursement: NAI500, SmartAsset, Focused Ultrasound Foundation reimbursement primer.

Flagged disputes: company revenue figures are FY2025 device-segment approximations that differ by source depending on segment definitions and acquisition treatment. Market-size figures and the "2–5x value on clearance" and "~99% via 510(k)" claims are widely cited rules of thumb / aggregator estimates, not audited statistics — qualified accordingly. PMA timeline/cost ranges describe the full clinical-development cycle (FDA review alone is months-to-over-a-year). Multiple ranges are sentiment- and rate-dependent.